Home > John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL
Lymphoma

John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL

Published Online: June 4th 2020

John Kuruvilla joins us to discuss the presentation a the ASCO20 Virtual Meeting of the results of the KEYNOTE-204 trial, the first positive phase III trial of an anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma.

Questions

1. What are the unmet needs in the treatment of classical Hodgkin lymphoma? (0:06)

2. Could you give us an overview of the aims and design of the KEYNOTE-204 study? (1:40)

3. What were the key efficacy and safety findings of this study? (2:30)

4. How will these data impact on the treatment landscape and what are the next steps following this research? (4:40)

5. In which other haematological malignancies is pembrolizumab being investigated? (5:56)

 

Speaker disclosure: John Kuruvilla has received honoraria and consulting fees from Merck and Seattle Genetics.

Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.

Share this Video
Related Videos In Lymphoma
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar